The impact of the clinical phase and intellectual property on post-IPO performance of biotech companies that went public between 2018 and 2022 on the NASDAQ

Additional Metadata
Keywords	Biotech, IPO, Intellectual property, Clinical success, post-IPO performance, NASDAQ
Thesis Advisor	Urquhart, Andrew, Paaso, Mikael
Persistent URL	hdl.handle.net/2105/71773
Series	Finance & Investments
Organisation	Rotterdam School of Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Lelieveld, Michelle. (2024, April 23). The impact of the clinical phase and intellectual property on post-IPO performance of biotech companies that went public between 2018 and 2022 on the NASDAQ. Finance & Investments. Retrieved from http://hdl.handle.net/2105/71773

Publication